The COVID-19 pandemic exposed the dangers of Africa’s heavy dependence on foreign pharmaceutical supplies. As wealthier nations prioritised their own populations during the global crisis, African countries found themselves at the back of the vaccine supply chain, struggling to secure lifesaving doses and essential medical products.
That defining moment triggered a major shift in African health policy, centred on one strategic objective: building long-term health self-reliance.
READ ALSO: Ghana’s Fight Against Malaria: Vaccines Saving Children’s Lives
Today, Africa’s vaccine manufacturing drive is no longer a symbolic ambition or a recurring conference theme. It is rapidly becoming one of the continent’s most important industrial transformations, linking healthcare, biotechnology, scientific research, trade, industrial policy, and economic sovereignty into a unified continental agenda.
What is emerging is not simply a pharmaceutical sector but the foundation of Africa’s future health security architecture.
The African Union (AU), the Africa Centres for Disease Control and Prevention (Africa CDC), regional governments, development finance institutions, and private-sector manufacturers are now aligned behind a historic goal: producing 60 percent of Africa’s vaccine needs locally by 2040.
For a continent that previously manufactured less than 1 percent of its vaccines, this represents a significant strategic shift. The effort goes far beyond medicine. It has become a defining test of Africa’s ability to industrialise strategically, retain scientific talent, strengthen research capacity, and build resilient systems capable of protecting both lives and economies.
Africa’s vaccine dependence did not emerge overnight. It was the result of decades of structural underinvestment in scientific infrastructure, fragmented regulatory systems, weak pharmaceutical manufacturing capacity, and a development model focused more on procurement than production.
For years, public health systems across the continent relied heavily on donor-funded vaccination programmes and external supply chains dominated by Europe, North America, India, and China. While this arrangement functioned imperfectly during stable periods, it left Africa dangerously exposed during global emergencies.
The COVID-19 pandemic transformed that vulnerability into a full-scale crisis. Wealthy countries secured advance purchase agreements and controlled production capacity, while African nations faced severe delays in accessing vaccines, therapeutics, and critical medical supplies.
Even global initiatives such as COVAX struggled to close the gap quickly enough.
The lesson was clear and unavoidable: health security cannot depend entirely on external goodwill. What began as a public health emergency quickly evolved into an economic, industrial, and geopolitical reckoning.
Africa’s response has been both ambitious and strategic. Through initiatives such as the African Union’s Partnerships for African Vaccine Manufacturing (PAVM) and the New Public Health Order, the continent established a measurable target of producing 60 percent of its vaccines locally by 2040.
The vision extends far beyond simple packaging or fill-and-finish operations. It includes building complete manufacturing ecosystems that integrate research, regulation, logistics, workforce development, and scientific innovation.
Importantly, vaccine manufacturing is now being viewed not only as health policy but also as a gateway into the broader knowledge economy, helping Africa build expertise in genomics, biotechnology, biomanufacturing, and data science.
Momentum is increasingly shifting from policy discussions to implementation.
Gavi’s African Vaccine Manufacturing Accelerator has committed approximately $1.2 billion over ten years to help stabilise demand and reduce commercial risk for African manufacturers. Institutions such as the African Export-Import Bank (Afreximbank), the European Investment Bank, and the International Finance Corporation are also supporting vaccine production facilities across the continent.
In South Africa, companies such as Aspen and Biovac are expanding manufacturing capacity, while Senegal’s Institut Pasteur de Dakar is advancing modular production systems. Rwanda has partnered with BioNTech to establish mRNA production facilities, and Ghana became the first African country to produce a locally developed cholera vaccine through DEK Vaccines. Egypt and Morocco are also scaling export-oriented pharmaceutical production.
Beyond healthcare, the vaccine manufacturing drive carries major economic implications. Local production could help Africa retain billions of dollars currently lost through pharmaceutical imports while creating high-skilled jobs, strengthening scientific workforces, and reducing exposure to global supply disruptions and currency volatility.
Despite this momentum, major structural challenges remain.
Africa still depends heavily on external suppliers for critical inputs such as lipid nanoparticles, specialised reagents, and advanced manufacturing materials. Intellectual property restrictions continue to limit access to some cutting-edge technologies, particularly in areas such as mRNA development.
At the same time, African-made vaccines must compete with heavily subsidised imports, while long-term political commitment and financing will be essential to ensure that emerging projects reach full commercial sustainability.
Geopolitically, however, the implications of success are enormous.
A strong pharmaceutical manufacturing base would provide Africa with greater strategic autonomy and stronger negotiating power within the global health system. It also forms part of a broader continental push for sovereignty across digital infrastructure, industrial production, supply chains, and technological development.
Africa is no longer merely discussing health sovereignty. It is actively building it.
The continent’s ambition is now unmistakable: the next global health crisis must find Africa not at the back of the queue, but at the centre of its own solution.
